Hospitals prevent deadly fungal infection during pandemic

Hospitals prevent deadly fungal infection during pandemic

As COVID-19 infections threatened to overwhelm hospitals in March 2020,
infection control specialists worried not just about SARS-CoV-2 but also about
other viral, bacterial and fungal diseases.

C. auris is a type of fungus that causes severe, often
fatal infections and is resistant to most antifungal drugs. It can be carried
on a patient’s skin and can survive on surfaces for more than a month, allowing
it to spread easily among patients. Most hospital disinfectants cannot
kill C. auris, making it difficult to eradicate from the healthcare
environment. It is also easy to misidentify in lab tests.

In the midst of the COVID-19 pandemic, infection control experts at two
Southern California hospitals – Scripps Memorial in La Jolla and UCLA Health in
Los Angeles – took extreme measures to stop the spread of a deadly fungus.
Their findings were shared at the Association for Professionals in Infection
Control and Epidemiology’s (APIC) 48th annual conference.

During the initial influx of COVID-19 patients, Dr Elizabeth A.
Jefferson of Scripps Memorial was notified that her facility had received the
first known case of C. auris in San Diego County. Initially
flagged and isolated because the patient had received healthcare abroad,
laboratory tests confirmed C. auris in a wound.

The patient remained hospitalised in isolation for 47 days, during which
time the team implemented aggressive cleaning measures, including use of a disinfectant
that was effective against C. auris and UV light for terminal
cleaning of all patient rooms.

‘Education of staff was essential,’ said Dr Jefferson. ‘Staff had to
clean and disinfect the room twice a day, and then clean any shared equipment,
because if Candida auris sets up shop in your facility, it is
extremely difficult to get rid of.’

As a result, there was no transmission of the fungal pathogen that has
infected nearly 1,800 patients in 15 states and the District of Columbia since
it was first detected in the U.S. in 2015.

When C. auris started to surge in Southern California
during the summer of 2020, UCLA Health had already created a multi-level
notification system designed to catch potential cases early and prevent

Collaborating with their electronic medical records (EMR) team and the
lab, the infection preventionists made sure the EMR system was set up to screen
every patient for both COVID and Candida auris when they
entered the facility.

High-risk patients were flagged and tested with subsequent notifications
sent to infection prevention, environmental services, the lab, and nursing. The
system triggered reminders for stringent cleaning protocols which included
testing of environmental surfaces after terminal cleaning to ensure that the
patient’s room was clear of the organism.

‘Having an in-house lab that could test for C. auris and
collaborating with the EMR team to build a set of screening steps into our EMR
created a failsafe way to ensure we could monitor and track any suspected C.
 cases at our facility. This process was effective in prevention
of cross contamination in the healthcare environment,’ said Dr Urvashi Parti,
at UCLA Health.

‘The fact that these two teams recognised this threat and were able to
mobilise so quickly and effectively while also on high alert for COVID is
remarkable,’ said APIC 2021 President Ann Marie Pettis, ‘Their case studies
demonstrate how important it is that hospitals, clinics, and long-term care
facilities have enough infection preventionists and resources to train staff
and monitor safety protocols so they can prevent harm on multiple fronts.’

Leave a Reply

Your email address will not be published. Required fields are marked *